Acalabrutinib Chronic Lymphocytic Leukemia trial
A new phase 2 trial, NCT07582159, adds acalabrutinib to tafasitamab and venetoclax in CLL/SLL; BioQ shows its BTK potency and 121 registered trials.
BioQ Blog
Every BioQ post about acalabrutinib: real search results, sources and the query to repeat it.
A new phase 2 trial, NCT07582159, adds acalabrutinib to tafasitamab and venetoclax in CLL/SLL; BioQ shows its BTK potency and 121 registered trials.